Early ablation leads to better outcome in patients < 55 years with persistent atrial fibrillation.
Catheter ablation
Diagnosis-to-ablation time
Persistent atrial fibrillation
Young patients
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
02
08
2024
accepted:
10
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
The question of optimal timing for catheter ablation of atrial fibrillation (AF) to achieve best outcomes remains a crucial clinical issue. As AF occurs less frequently in younger patients, data regarding Diagnosis-to-Ablation Time (DAT) is especially limited in patients under the age of 55 years with persistent AF. We therefore analyzed the temporal relationship between initial AF presentation and timing of catheter ablation in this cohort. We conducted a retrospective single-centre study of patients ≤ 55 years with persistent AF who underwent first-time catheter ablation at our center. The cohort was divided into patients that underwent catheter ablation after diagnosis of persistent AF within a DAT of ≤ 12 months and patients with a DAT of > 12 months. A total of 101 patients (median age 51 years; female n = 19 (18.8%)) with persistent AF were included. Ablation was performed within 12 months ("early DAT") in 51 patients and > 12 months ("late DAT") in 50 patients. Pulmonary vein isolation was performed using high-power short-duration (HPSD) radiofrequency ablation. Median DAT was 5 months (1-12 months) in the early ablation group and 36 months (13-240 months) in the late ablation group. The median follow-up was 11.3 months (0.03-37.1 months). The rate of any atrial arrhythmia recurrence after a 30-day blanking period was significantly lower in the early DAT group (13/51 patients; 25.5%) as compared to the late DAT group (26/50 patients; 52.0%) (log rank test; p = 0.003). Catheter ablation performed > 12 months after the initial AF diagnosis was an independent predictor for the occurrence of any atrial arrythmia (OR: 2.58; (95%-CI: 1.32-5.07). Early first-time catheter ablation (DAT ≤ 12 months) in patients ≤ 55 years with persistent AF is associated with a significantly lower rate of arrhythmia recurrence.
Identifiants
pubmed: 39455654
doi: 10.1038/s41598-024-76098-2
pii: 10.1038/s41598-024-76098-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25370Informations de copyright
© 2024. The Author(s).
Références
Vermond, R. A. et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: A community-based study from the Netherlands. J. Am. Coll. Cardiol. 66(9), 1000–1007 (2015).
doi: 10.1016/j.jacc.2015.06.1314
pubmed: 26314526
Tseng, A. S. et al. One-year outcomes of catheter ablation for atrial fibrillation in young patients. BMC Cardiovasc. Disord. 23(1), 83 (2023).
doi: 10.1186/s12872-022-03017-6
pubmed: 36774486
pmcid: 9921413
Kirchhof, P. et al. Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med. 383(14), 1305–1316 (2020).
doi: 10.1056/NEJMoa2019422
pubmed: 32865375
Hindricks, G. et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42(5), 373–498 (2021).
doi: 10.1093/eurheartj/ehaa612
pubmed: 32860505
Bunch, T. J. et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm 10(9), 1257–1262 (2013).
doi: 10.1016/j.hrthm.2013.05.013
pubmed: 23702238
Johnson, B. M. et al. Atrial fibrillation ablation in young adults: Measuring quality of life using patient-reported outcomes over 5 years. Circ. Arrhythm. Electrophysiol. 16(6), e011565 (2023).
doi: 10.1161/CIRCEP.122.011565
pubmed: 37183675
pmcid: 11093280
Kottmaier, M. et al. Safety and outcome of very high-power short-duration ablation using 70 W for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. Ep Europace 22(3), 388–393 (2020).
doi: 10.1093/europace/euz342
Bourier, F. et al. High-power short-duration versus standard radiofrequency ablation: Insights on lesion metrics. J. Cardiovasc. Electrophysiol. 29(11), 1570–1575 (2018).
doi: 10.1111/jce.13724
pubmed: 30168230
Popa, M. A. et al. Safety profile and long-term efficacy of very high-power short-duration (60–70 W) catheter ablation for atrial fibrillation: Results of a large comparative analysis. Europace 25, 408–416 (2023).
doi: 10.1093/europace/euac215
pubmed: 36504120
Wazni, O. M. et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N. Engl. J. Med. 384(4), 316–324 (2020).
doi: 10.1056/NEJMoa2029554
pubmed: 33197158
Verma, A. et al. Approaches to catheter ablation for persistent atrial fibrillation. N. Engl. J. Med. 372(19), 1812–1822 (2015).
doi: 10.1056/NEJMoa1408288
pubmed: 25946280
Kistler, P. M. et al. Effect of catheter ablation using pulmonary vein isolation with vs without posterior left atrial wall isolation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: The CAPLA randomized clinical trial. JAMA 329(2), 127–135 (2023).
doi: 10.1001/jama.2022.23722
pubmed: 36625809
pmcid: 9856612
Huo, Y. et al. Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation. NEJM Evid. 1(11), EVIDoa2200141 (2022).
doi: 10.1056/EVIDoa2200141
pubmed: 38319851
Kirchhof, P. & Calkins, H. Catheter ablation in patients with persistent atrial fibrillation. Eur. Heart J. 38(1), 20–26 (2016).
doi: 10.1093/eurheartj/ehw260
pubmed: 27389907
pmcid: 5353871
Kalman, J. M. et al. Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences. Eur. Heart J. 44, 2447–2454 (2023).
doi: 10.1093/eurheartj/ehad247
pubmed: 37062010
Chew, D. S. et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: A systematic review and meta-analysis of observational studies. Circ. Arrhythm. Electrophysiol. 13(4), e008128 (2020).
doi: 10.1161/CIRCEP.119.008128
pubmed: 32191539
pmcid: 7359927
Andrade, J. G. et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N. Engl. J. Med. 384(4), 305–315 (2020).
doi: 10.1056/NEJMoa2029980
pubmed: 33197159
Ding, W. Y. et al. Impact of early ablation of atrial fibrillation on long-term outcomes: Results from phase II/III of the GLORIA-AF registry. Clin. Res. Cardiol. 111(9), 1057–1068 (2022).
doi: 10.1007/s00392-022-02022-1
pubmed: 35488127
pmcid: 9424157
Andrade, J. G. et al. Progression of atrial fibrillation after cryoablation or drug therapy. N. Engl. J. Med. 388(2), 105–116 (2022).
doi: 10.1056/NEJMoa2212540
pubmed: 36342178
Nattel, S. & Harada, M. Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J. Am. Coll. Cardiol. 63(22), 2335–2345 (2014).
doi: 10.1016/j.jacc.2014.02.555
pubmed: 24613319
Kottkamp, H. Human atrial fibrillation substrate: Towards a specific fibrotic atrial cardiomyopathy. Eur. Heart J. 34(35), 2731–2738 (2013).
doi: 10.1093/eurheartj/eht194
pubmed: 23761394
Quah, J. X. et al. Atrial fibrosis and substrate based characterization in atrial fibrillation: Time to move forwards. J. Cardiovasc. Electrophys. 32(4), 1147–1160 (2021).
doi: 10.1111/jce.14987
Andrade, J. G. et al. Atrial fibrillation progression after cryoablation vs. radiofrequency ablation: The CIRCA-DOSE trial. Eur. Heart J. 45(7), 510–518 (2024).
doi: 10.1093/eurheartj/ehad572
pubmed: 37624879
Reddy, V. Y. et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N. Engl. J. Med. 389(18), 1660–1671 (2023).
doi: 10.1056/NEJMoa2307291
pubmed: 37634148
Feinberg, W. M., Blackshear, J. L., Laupacis, A., Kronmal, R. & Hart, R. G. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch. Intern. Med. 155(5), 469–473 (1995).
doi: 10.1001/archinte.1995.00430050045005
pubmed: 7864703
Zhang, X.-D. et al. The impact of age on the efficacy and safety of catheter ablation for long-standing persistent atrial fibrillation. Int. J. Cardiol. 168(3), 2693–2698 (2013).
doi: 10.1016/j.ijcard.2013.03.025
pubmed: 23562463
Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adultsnational implications for rhythm management and stroke prevention: The AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285(18), 2370–2375 (2001).
doi: 10.1001/jama.285.18.2370
pubmed: 11343485
Leong-Sit, P. et al. Efficacy and risk of atrial fibrillation ablation before 45 years of age. Circ. Arrhythm. Electrophysiol. 3(5), 452–457 (2010).
doi: 10.1161/CIRCEP.110.938860
pubmed: 20858861